Comparative Pharmacology
Head-to-head clinical analysis: BARICITINIB versus TOFACITINIB CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARICITINIB versus TOFACITINIB CITRATE.
BARICITINIB vs TOFACITINIB CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Baricitinib is a Janus kinase (JAK) inhibitor, selectively inhibiting JAK1 and JAK2, thereby modulating the signaling pathway involved in inflammatory responses.
Janus kinase (JAK) inhibitor; inhibits JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), thereby modulating cytokine signaling and downregulating immune and inflammatory responses.
2 mg orally once daily; may increase to 4 mg once daily if inadequate response.
5 mg orally twice daily for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; 10 mg orally twice daily for ulcerative colitis induction (8 weeks maximum).
None Documented
None Documented
Terminal elimination half-life is approximately 12.5 hours in healthy subjects; allowing once-daily dosing with steady-state reached in 2-3 days.
Clinical Note
moderateBaricitinib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Baricitinib."
Clinical Note
moderateBaricitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Cyclosporine
Terminal elimination half-life is approximately 3 hours (range 2–4 hours) in patients with normal renal function, allowing twice-daily dosing. Half-life is prolonged in moderate to severe renal impairment (up to 5–8 hours) and in hepatic impairment.
Approximately 75% of the dose is excreted in urine (69% as unchanged drug, 6% as metabolites), and 20% in feces (15% unchanged, 5% metabolites).
Approximately 70% of the dose is eliminated by hepatic metabolism, with about 30% excreted unchanged in urine and <10% in feces. Renal excretion accounts for ~30% of total clearance.
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Baricitinib."